Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

Andrew H. Wei; Ing S. Tiong

doi:10.1182/blood-2017-08-784066

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

Andrew H. Wei, Ing S. Tiong

Australian Centre for Blood Diseases

Research output: Contribution to journal › Review Article › Research › peer-review

113 Citations (Scopus)

Abstract

In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.

Original language	English
Pages (from-to)	2469-2474
Number of pages	6
Journal	Blood
Volume	130
Issue number	23
DOIs	https://doi.org/10.1182/blood-2017-08-784066
Publication status	Published - 7 Dec 2017

Access to Document

10.1182/blood-2017-08-784066

283147514-oaFinal published version, 543 KB

Cite this

@article{5ff1f98178c14f4fa144dee699873a7c,

title = "Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML",

abstract = "In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.",

author = "Wei, {Andrew H.} and Tiong, {Ing S.}",

year = "2017",

month = dec,

day = "7",

doi = "10.1182/blood-2017-08-784066",

language = "English",

volume = "130",

pages = "2469--2474",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "23",

}

TY - JOUR

T1 - Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

AU - Wei, Andrew H.

AU - Tiong, Ing S.

PY - 2017/12/7

Y1 - 2017/12/7

N2 - In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.

AB - In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.

UR - http://www.scopus.com/inward/record.url?scp=85037659226&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-08-784066

DO - 10.1182/blood-2017-08-784066

M3 - Review Article

C2 - 29051180

AN - SCOPUS:85037659226

SN - 0006-4971

VL - 130

SP - 2469

EP - 2474

JO - Blood

JF - Blood

IS - 23

ER -

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

Abstract

Access to Document

Other files and links

Cite this